Jaleh Barar  , Yadollah Omidi*
|
Yadollah Omidi , Jaleh Barar*
|
Jaleh Barar*
|
Mohammad Reza Asgharzadeh, Jaleh Barar , Mohammad M. Pourseif, Morteza Eskandani, Mojtaba Jafari Niya, Mohammad Reza Mashayekhi, Yadollah Omidi*
|
Mitra Dolatkhah, Yadollah Omidi*
Dr. Yadollah Omidi (Pharm.D., Ph.D.) is a Professor of Pharmaceutical Sciences at TUOMS Faculty of Pharmacy, working on advanced multifunctional nanobiosystems. He has worked at Cardiff University and University of Pennsylvania. He has published over 210 papers and 18 book chapters, supervised and mentored over 100 graduate/postgraduate students/researchers.
|
Leila Rostamizadeh , Ommoleila Molavi* , Mohsen Rashid, Fatemeh Ramazani, Behzad Baradaran, Afsaneh Lavasanaifar, Raymond Lai
In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
|
Xiuying Li* , Xianqin Luo, Shunqin Hu
Our results indicated that losartan can modulate the tumor microenvironment, and improve the efficacy of anti-PD-L1 mAb.
|
Nazila Jalilzadeh , Neda Barzgar Barough, Mehrdad Karami, Amir Baghbanzadeh, Kobra Velaei*
|
Nazanin Jamshidi , Negar Jamshidi , Amir Modarresi Chahardehi , Elahe Shams , Vahid Chaleshi*
|
Fariba Nikravesh , Hossein Arezoomand , Roohollah h Mirzaee Khalilabadi, Maryam Nooshadokht, Hajar Mardani Valandani*
|
Milad Asadi , Venus Zafari, Sanam Sadeghi-Mohammadi, Dariush Shanehbandi, Ufuk Mert, Zahra Soleimani, Ayşe Caner, Habib Zarredar*
|